Product

Company

NCT03564275·1 site·ClinicalTrials.gov

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University of Cincinnati

Age

18–any

Sex

MALE

Healthy volunteers

Not accepted

≥18 years of age
Diagnosis of low risk prostate cancer (T1c-T2a, Gleason 6, Prostate Specific Antigen (PSA) \<10) -OR-
Diagnosis of intermediate risk prostate cancer (T1c-T2c, Gleason 7 and/or PSA 10- 20)
Life expectancy \>10 yrs
Physically and mentally capable of signing the consent form of their own volition

\< 18 years of age
Diagnosis of high risk prostate cancer (T3 or higher, Gleason \>7 and/or PSA \>20)
Current or historical use of androgen deprivation therapy
Nodal positivity
Previous cancer excluding non-melanoma skin cancer
History of prostatectomy
History of brachytherapy for prostate cancer
Life expectancy \<10 yrs
Physically or mentally incapable of signing the consent form of their own volition

The record

StatusActive not recruiting

PhaseNo phase

Taking part10

StartedApr 2018

UpdatedMay 31, 2025

Conditions

Where1

Clareo Health | Proton Boost in Prostate Cancer